Recent Finacing
Recent Raise
GeNeuro is a Geneva-based clinical-stage biopharma developing monoclonal antibodies (temelimab/GNbAC1) targeting HERV‑W/Env proteins for MS and post-COVID neuropsychiatric syndromes, running biomarker-selected Phase II trials and partnerships.
